An increased risk of cardiovascular disease may be present as early as 30 years before a type 2 diabetes diagnosis is made, ...

Much remains to learn about this anatomical finding, seen in about one-third of adults, and how it may affect stroke risk.

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.

These data should help reassure those concerned with the risks of educating physicians through live cases at medical meetings ...

A multistate model that enables real-time risk recalculations may help improve risk stratification for prediction of ...

There remains a need to identify patients who will derive benefits from adjunctive techniques on top of pulmonary vein ...

Investigators saw more deaths in patients with severe TR after repeat mitral valve procedures; what to do about it is unclear ...

Janar Sathananthan, Ole De Backer, and Michael Reardon dive into the newest findings on TAVR from the late-breaking ACURATE IDE trial.

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

The study was stopped early to allow all patients with advanced PAH the option for treatment with the activin signaling ...

In the waning days of the Biden-Harris administration, the US Centers for Medicare & Medicaid Services (CMS) has proposed changes that would allow the glucagon-like peptide-1 (GLP-1) receptor agonists ...